|
|
Matthew H. Kulke, MD
Publications
- Wu IC, Zhao Y, Zhai R, Liu CY, Chen F, Ter-Minassian M, Asomaning K, Su L, Heist RS, Kulke MH, Liu G, Christiani DC.Interactions between genetic polymorphisms in the apoptotic pathway and environmental factors on esophageal adenocarcinoma risk.Carcinogene
21212151 - Chan JA, Kulke MH.New Treatment Options for Patients with Advanced Neuroendocrine Tumors.Curr Treat Options Oncol. 2011 Mar 25.
21437592 - Raut CP, Kulke MH.Targeted therapy in advanced well-differentiated neuroendocrine tumors.Oncologist. 2011;16(3):286-95.
21346024 - Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, Ellis LM, Benedetti JK, Bergsland EK, Hobday TJ, Van Cutsem E, Pingpank J, Oberg K, Cohen SJ, Posner MC, Yao JC.Future directions in the treatment of neuroendocrine tumors: consensus report of the
21263089 - Walsh KM, Choi M, Oberg K, Kulke MH, Yao JC, Wu C, Jurkiewicz M, Hsu LI, Hooshmand SM, Hassan M, Janson ET, Cunningham JL, Vosburgh E, Sackler RS, Lifton RP, Dewan AT, Hoh J.A pilot genome-wide association study shows genomic variants enriched in the non-
21139019 - Kulke MH, Chan JA, Meyerhardt JA, Zhu AX, Abrams TA, Blaszkowsky LS, Regan E, Sidor C, Fuchs CS.A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors.Cancer Chemother P
20960192 - Chan JA, Zhu AX, Stuart K, Bhargava P, Earle CC, Clark JW, Casey C, Regan E, Kulke MH.Phase II study of pemetrexed in patients with advanced neuroendocrine tumors.Cancer Chemother Pharmacol. 2010 Oct;66(5):961-8.
20130879 - Strosberg JR, Coppola D, Klimstra DS, Phan AT, Kulke MH, Wiseman GA, Kvols LK.The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas.Pancreas. 2010 Aug;39(6):799-800.
20664477 - Kulke MH, Anthony LB, Bushnell DL, de Herder WW, Goldsmith SJ, Klimstra DS, Marx SJ, Pasieka JL, Pommier RF, Yao JC, Jensen RT.NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas.Pancreas. 2010 Aug;39(6):735-
20664472 - Liu CY, Wu MC, Chen F, Ter-Minassian M, Asomaning K, Zhai R, Wang Z, Su L, Heist RS, Kulke MH, Lin X, Liu G, Christiani DC.A Large Scale Genetic Association Study of Esophageal Adenocarcinoma Risk.Carcinogenesis. 2010 Jul;31(7):1259-63.
20453000 - Zhai R, Chen F, Liu G, Su L, Kulke MH, Asomaning K, Lin X, Heist RS, Nishioka NS, Sheu CC, Wain JC, Christiani DC.Interactions among genetic variants in apoptosis pathway genes, reflux symptoms, body mass index, and smoking indicate two distinct etiologic
20385987 - Klimstra DS, Modlin IR, Adsay NV, Chetty R, Deshpande V, Gönen M, Jensen RT, Kidd M, Kulke MH, Lloyd RV, Moran C, Moss SF, Oberg K, O'Toole D, Rindi G, Robert ME, Suster S, Tang LH, Tzen CY, Washington MK, Wiedenmann B, Yao J.Pathology reporting of
20118772 - Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen S, St Peter J, Haas T, Lebwohl D, Van Cutsem E, Kulke MH, Hobday TJ, O'Dorisio TM, Shah MH, Cadiot G, Luppi G, Posey JA, Wiedenmann B.Daily oral everolimus activity in pati
19933912 - Kulke MH, Scherübl H.Accomplishments in 2008 in the management of gastrointestinal neuroendocrine tumors.Gastrointest Cancer Res. 2009 Sep;3(5 Supplement 2):S62-6.
20011568 - Kulke MH, Tempero MA, Niedzwiecki D, Hollis DR, Kindler HL, Cusnir M, Enzinger PC, Gorsch SM, Goldberg RM, Mayer RJ.Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in pa
19858396 - Bradbury PA, Kulke MH, Heist RS, Zhou W, Ma C, Xu W, Marshall AL, Zhai R, Hooshmand SM, Asomaning K, Su L, Shepherd FA, Lynch TJ, Wain JC, Christiani DC, Liu G.Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes.Pharmacoge
19620936 - Cheung WY, Zhai R, Kulke MH, Heist RS, Asomaning K, Ma C, Wang Z, Su L, Lanuti M, Tanabe KK, Christiani DC, Liu G.Epidermal growth factor A61G gene polymorphism, gastroesophageal reflux disease and esophageal adenocarcinoma risk.Carcinogenesis. 2009 Aug;3
19520791 - Souglakos J, Philips J, Wang R, Marwah S, Silver M, Tzardi M, Silver J, Ogino S, Hooshmand S, Kwak E, Freed E, Meyerhardt JA, Saridaki Z, Georgoulias V, Finkelstein D, Fuchs CS, Kulke MH, Shivdasani RA.Prognostic and predictive value of common mutations f
19603024 - Clark OH, Benson AB, Berlin JD, Choti MA, Doherty GM, Engstrom PF, Gibbs JF, Heslin MJ, Kessinger A, Kulke MH, Kvols L, Salem R, Saltz L, Shah MH, Shibata S, Strosberg JR, Yao JC, .NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors.J Na
19635226 - Bradbury PA, Zhai R, Ma C, Xu W, Hopkins J, Kulke MJ, Asomaning K, Wang Z, Su L, Heist RS, Lynch TJ, Wain JC, Christiani D, Liu G.Vascular endothelial growth factor polymorphisms and esophageal cancer prognosis.Clin Cancer Res. 2009 Jul 15;15(14):4680-5.
19584152 - Cescon DW,Bradbury PA,Asomaning K,Hopkins J,Zhai R,Zhou W,Wang Z,Kulke M,Su L,Ma C,Xu W,Marshall AL,Heist RS,Wain JC,Lynch TJ Jr,Christiani DC,Liu G.p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosis.Clin Cancer Res. 200
19383811 - Chan JA,Kulke MH.Progress in the treatment of neuroendocrine tumors.Curr Oncol Rep. 2009 May;11(3):193-9. Review.
19336011 - Bradbury PA,Zhai R,Hopkins J,Kulke MH,Heist RS,Singh S,Zhou W,Ma C,Xu W,Asomaning K,Ter-Minassian M,Wang Z,Su L,Christiani DC,Liu G.Matrix metalloproteinase 1, 3 and 12 polymorphisms and esophageal adenocarcinoma risk and prognosis.Carcinogenesis. 2009 Ma
19321798 - Kulke MH,Hornick JL,Frauenhoffer C,Hooshmand S,Ryan DP,Enzinger PC,Meyerhardt JA,Clark JW,Stuart K,Fuchs CS,Redston MS.O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.Clin
19118063 - Zhai R,Liu G,Asomaning K,Su L,Kulke MH,Heist RS,Nishioka NS,Lynch TJ,Wain JC,Lin X,Christiani DC.Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure and esophageal adenocarcinoma risk.Carcinogenesis. 2008 Dec;29(12):2330-4.
18780893 - Bracht LK,Wen P,Meyerhardt JA,Kulke MH,Hornick JL,Redston M,LaFrankie DC,Black PM,Kesari S,Norden A,Drappatz J.DNA repair enzyme expression and differential response to temozolomide in a patient with both glioblastoma and metastatic pancreatic neuroendocr
18779600 - Fujiki K,Duerr EM,Kikuchi H,Ng A,Xavier RJ,Mizukami Y,Imamura T,Kulke MH,Chung DC.Hoxc6 is overexpressed in gastrointestinal carcinoids and interacts with JunD to regulate tumor growth.Gastroenterology. 2008 Sep;135(3):907-16, 916.e1-2.
18655788 - Sheehy N,Kulke MH,Van den Abbeele AD.F-18 FDG PET/CT in the diagnosis and management of a pericardiac paraganglioma.Clin Nucl Med. 2008 Aug;33(8):545-6.
18645373 - Kulke MH,Lenz HJ,Meropol NJ,Posey J,Ryan DP,Picus J,Bergsland E,Stuart K,Tye L,Huang X,Li JZ,Baum CM,Fuchs CS.Activity of sunitinib in patients with advanced neuroendocrine tumors.J Clin Oncol. 2008 Jul 10;26(20):3403-10.
18612155 - Li J, Wang L, Mamon H, Kulke MH, Berbeco R, Makrigiorgos GM.Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing.Nat Med. 2008 May;14(5):579-84.
18408729 - Kulke MH,Freed E,Chiang DY,Philips J,Zahrieh D,Glickman JN,Shivdasani RA.High-resolution analysis of genetic alterations in small bowel carcinoid tumors reveals areas of recurrent amplification and loss.Genes Chromosomes Cancer. 2008 Jul;47(7):591-603.
18383209 - Duerr EM, Mizukami Y, Ng A, Xavier RJ, Kikuchi H, Deshpande V, Warshaw AL, Glickman J, Kulke MH, Chung DC.Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis.Endocr Relat Cancer. 2
18310291 - Meyerhardt JA, Zhu AX, Stuart K, Ryan DP, Blaszkowsky L, Lehman N, Earle CC, Kulke MH, Bhargava P, Fuchs CS.Phase-II Study of Gemcitabine and Cisplatin in Patients with Metastatic Biliary and Gallbladder Cancer.Dig Dis Sci. 2008 Feb;53(2):564-70.
17597402 - Bradbury PA, Heist RS, Kulke MH, Zhou W, Marshall AL, Miller DP, Su L, Park S, Temel J, Fidias P, Sequist L, Lynch TJ, Wain JC, Shepherd FA, Christiani DC, Liu G.A rapid outcomes ascertainment system improves the quality of prognostic and pharmacogenetic
18199725 - Kulke MH, Blaszkowsky LS, Ryan DP, Clark JW, Meyerhardt JA, Zhu AX, Enzinger PC, Kwak EL, Muzikansky A, Lawrence C, Fuchs CS.Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.J Clin Oncol. 2007 Oct 20;25(30):4787-92.
17947726 - Plockinger U, Couvelard A, Falconi M, Sundin A, Salazar R, Christ E, de Herder WW, Gross D, Knapp WH, Knigge UP, Kulke MH, Pape UF.Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated tumour/carcin
17934252 - Wang F, Wang L, Briggs C, Sicinska E, Gaston SM, Mamon H, Kulke MH, Zamponi R, Loda M, Maher E, Ogino S, Fuchs CS, Li J, Hader C, Makrigiorgos GM.DNA degradation test predicts success in whole-genome amplification from diverse clinical samples.J Mol Diagn
17690213 - Kulke MH.Gastrointestinal neuroendocrine tumors: a role for targeted therapies?.Endocr Relat Cancer. 2007 Jun;14(2):207-19. Review.
17639038 - Schwarzberg AB, Stover EH, Sengupta T, Michelini A, Vincitore M, Baden LR, Kulke MH.Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temozolomide.Cancer Invest. 2007 Jun;25(4):249-55.
17612935 - Kulke MH.Clinical presentation and management of carcinoid tumors.Hematol Oncol Clin North Am. 2007 Jun;21(3):433-55; vii-viii. Review.
17548033 - Kulke MH.New developments in the treatment of gastrointestinal neuroendocrine tumors.Curr Oncol Rep. 2007 May;9(3):177-83. Review.
17430688 - Ogino S, Meyerhardt JA, Kawasaki T, Clark JW, Ryan DP, Kulke MH, Enzinger PC, Wolpin BM, Loda M, Fuchs CS.CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma.Virchows Ar
17372756 - Zhu AX, Clark JW, Ryan DP, Meyerhardt JA, Enzinger PC, Earle CC, Fuchs CS, Regan E, Anbe H, Houghton M, Zhang J, Urrea P, Kulke MH.Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastroin
16786333 - Kulke MH, Bergsland EK, Ryan DP, Enzinger PC, Lynch TJ, Zhu AX, Meyerhardt JA, Heymach JV, Fogler WE, Sidor C, Michelini A, Kinsella K, Venook AP, Fuchs CS.Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors.J Cl
16877721 - Kulke MH, Wu B, Ryan DP, Enzinger PC, Zhu AX, Clark JW, Earle CC, Michelini A, Fuchs CS.A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors.Dig Dis Sci. 2006 Jun;51(6):1033-8.
16865563 - Kwak EL, Jankowski J, Thayer SP, Lauwers GY, Brannigan BW, Harris PL, Okimoto RA, Haserlat SM, Driscoll DR, Ferry D, Muir B, Settleman J, Fuchs CS, Kulke MH, Ryan DP, Clark JW, Sgroi DC, Haber DA, Bell DW.Epidermal growth factor receptor kinase domain mut
16857803 - Kulke MH, Wu B, Clark JW, Enzinger PC, Lynch TJ, Vincitore M, Michelini A, Fuchs CS.A phase II study of doxorubicin, cisplatin, and 5-fluorouracil in patients with advanced adenocarcinoma of the stomach or esophagus.Cancer Invest. 2006 Apr-May;24(3):229-3
16809148 - Raut CP, Kulke MH, Glickman JN, Swanson RS, Ashley SW.Carcinoid tumors.Curr Probl Surg. 2006 Jun;43(6):383-450. Review.
16781906 - Kulke MH, Muzikansky A, Clark J, Enzinger PC, Fidias P, Kinsella K, Michelini A, Fuchs CS.A Phase II trial of vinorelbine in patients with advanced gastroesophageal adenocarcinoma.Cancer Invest. 2006 Jun-Jul;24(4):346-50.
16777685 - Clancy TE, Sengupta TP, Paulus J, Ahmed F, Duh MS, Kulke MH.Alkaline phosphatase predicts survival in patients with metastatic neuroendocrine tumors.Dig Dis Sci. 2006 May;51(5):877-84.
16758309 - Meyerhardt JA, Zhu AX, Enzinger PC, Ryan DP, Clark JW, Kulke MH, Earle CC, Vincitore M, Michelini A, Sheehan S, Fuchs CS.Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer.J Clin On
16622264 - Li J, Wang F, Mamon H, Kulke MH, Harris L, Maher E, Wang L, Makrigiorgos GM.Antiprimer quenching-based real-time PCR and its application to the analysis of clinical cancer samples.Clin Chem. 2006 Apr;52(4):624-33.
16469859 - McCollum AD, Wu B, Clark JW, Kulke MH, Enzinger PC, Ryan DP, Earle CC, Michelini A, Fuchs CS.The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer.Am J Clin Oncol. 2006 Feb;29(1):40-4.
16462501 - Clark OH, Ajani J, Benson AB, Byrd D, Doherty GM, Engstrom PF, Ettinger DS, Gibbs JF, Heslin MJ, Kandeel F, Kessinger A, Kulke MH, Kvols L, Nemcek AA, Olson JA, Ratliff TW, Saltz L, Schteingart DE, Shah MH, Shibata S,.Neuroendocrine tumors.J Natl Compr Ca
16451769 - Li J, Harris L, Mamon H, Kulke MH, Liu WH, Zhu P, Mike Makrigiorgos G.Whole genome amplification of plasma-circulating DNA enables expanded screening for allelic imbalance in plasma.J Mol Diagn. 2006 Feb;8(1):22-30.
16436631 - Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A, Fuchs CS.Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.J Clin Oncol. 2006 Jan 20;24(3):401-6.
16421420 - Enzinger PC, Kulke MH, Clark JW, Ryan DP, Kim H, Earle CC, Vincitore MM, Michelini AL, Mayer RJ, Fuchs CS.A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma.Dig Dis Sci. 2005 Dec;50(12):2218
16416165 - Meyerhardt JA, Heseltine D, Campos H, Holmes MD, Willett WC, Winer EP, Enzinger PC, Bunnell CA, Kulke MH, Fuchs CS.Assessment of a dietary questionnaire in cancer patients receiving cytotoxic chemotherapy.J Clin Oncol. 2005 Nov 20;23(33):8453-60.
16293876 - Levine RL, George DJ, Kulke MH.Incidental discovery of an appendiceal carcinoid tumor and a renal cell carcinoma.Clin Adv Hematol Oncol. 2003 Feb;1(2):99-100; discussion 100.
16224385 - Ogino S, Meyerhardt JA, Cantor M, Brahmandam M, Clark JW, Namgyal C, Kawasaki T, Kinsella K, Michelini AL, Enzinger PC, Kulke MH, Ryan DP, Loda M, Fuchs CS.Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advance
16166444 - Zhu AX, Fuchs CS, Clark JW, Muzikansky A, Taylor K, Sheehan S, Tam K, Yung E, Kulke MH, Ryan DP.A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma.Oncologist. 2005 Jun-Jul;10(6):392-8.
15967833 - McCollum AD, Kulke MH, Ryan DP, Clark JW, Shulman LN, Mayer RJ, Bartel S, Fuchs CS.Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors.Am J Clin Oncol. 2004 Oct;27(5):485-8.
15596916 - Kulke MH, Kim H, Stuart K, Clark JW, Ryan DP, Vincitore M, Mayer RJ, Fuchs CS.A phase II study of docetaxel in patients with metastatic carcinoid tumors.Cancer Invest. 2004;22(3):353-9.
15493355 - Kulke MH, Kim H, Clark JW, Enzinger PC, Lynch TJ, Morgan JA, Vincitore M, Michelini A, Fuchs CS.A Phase II trial of gemcitabine for metastatic neuroendocrine tumors.Cancer. 2004 Sep 1;101(5):934-9.
15329900 - Kulke MH, Odze RD, Mueller JD, Wang H, Redston M, Bertagnolli MM.Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer.J Thorac Cardiovasc Surg
15173710 - Ryan DP, Clark JW, Kulke MH, Fuchs CS, Earle CC, Enzinger PC, Stuart K, Catarius KJ, Winkelmann J, Mayer RJ.A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer
14533439 - Kulke MH, Demetri GD, Sharpless NE, Ryan DP, Shivdasani R, Clark JS, Spiegelman BM, Kim H, Mayer RJ, Fuchs CS.A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer.Ca
12416897 - Fuchs CS, Clark JW, Ryan DP, Kulke MH, Kim H, Earle CC, Vincitore M, Mayer RJ, Stuart KE.A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma.Cancer. 2002 Jun 15;94(12):3186-91.
12115351 - Ryan DP, Kulke MH, Fuchs CS, Grossbard ML, Grossman SR, Morgan JA, Earle CC, Shivdasani R, Kim H, Mayer RJ, Clark JW.A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma.Cancer. 2002 Jan 1;94(1):97-103.
11815964 - Ellis FH, Xu X, Kulke MH, LoCicero J, Loda M.Malignant transformation of the esophageal mucosa is enhanced in p27 knockout mice.J Thorac Cardiovasc Surg. 2001 Oct;122(4):809-14.
11581618 - Kulke MH, Thakore KS, Thomas G, Wang H, Loda M, Eng C, Odze RD.Microsatellite instability and hMLH1/hMSH2 expression in Barrett esophagus-associated adenocarcinoma.Cancer. 2001 Apr 15;91(8):1451-7.
11301392 - Kulke MH, Odze RD, Thakore KS, Thomas G, Wang H, Loda M, Eng C.Allelic loss of 10q23, the PTEN tumour suppressor gene locus, in Barrett's oesophagus-associated adenocarcinoma.Br J Cancer. 2001 Mar 23;84(6):748-53.
11259087 - Cibas ES, Goss GA, Kulke MH, Demetri GD, Fletcher CD.Malignant epithelioid angiomyolipoma ('sarcoma ex angiomyolipoma') of the kidney: a case report and review of the literature.Am J Surg Pathol. 2001 Jan;25(1):121-6.
11145246 - Kulke MH, Mayer RJ.Carcinoid tumors.N Engl J Med. 1999 Mar 18;340(11):858-68.
10080850
|
